Trial Profile
ONO-4538 Phase 1 Study A Multicenter, Open-Label, Non-Comparative Study in Patients with Resectable Malignancies (Gastric Cancer/Non-Small Cell Lung Cancer)
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Ono Pharmaceutical
- 22 Jul 2022 Planned End Date changed from 31 Dec 2020 to 31 Oct 2022.
- 08 Jun 2021 Preliminary results (n=31) gastric cancer patients presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 24 Jul 2018 Status changed from not yet recruiting to recruiting.